IDH inhibitors combined with intensive chemotherapy regime is the main heterogeneous source of IDH inhibitor combined therapy subgroup (ORR, 2-year OS rate), which has shown the best therapeutic effect in all the studies on IDH inhibitor combined with other drugs in the treatment of newly diagnosed IDH-mutated AML patients. This evidence concerns the gene IDH2 and acute myeloid leukemia.